Influence of vitamin B6 on nausea (Nausea gravidarum)
- Conditions
- O21.0Mild hyperemesis gravidarum
- Registration Number
- DRKS00010769
- Lead Sponsor
- eibniz Universität Hannover, Institut für Lebensmittelwissenschaft und Humanernährung, Abteilung Ernährungsphysiologie und Humanernährung
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 150
Women with confirmed pregnancy to the end of the 10th week of pregnancy,
acute nausea during pregnancy (Nausea gravidarum)
deterioration of nausea gravidarium during the study period of two weeks;
intake of vitamin B6 supplements over 2 mg/day;
taking any medications against nausea and vomiting;
previous hospitalization due to nausea gravidarum;
BMI =30kg/m2;
Blood pressure: >160mmHg systolic or >100mmHg diastolic;
multiple pregnancy;
known complications in an earlier pregnancy (e.g. premature delivery, miscarriage, placental abnormalities, fetal anomaly);
severe chronic illness (manifest coronary heart disease, cancer);
insulin-dependent diabetes mellitus Typ I and II;
severe kidney or liver diseases;
conditions after gastrointestinal surgical procedure and chronic gastrointestinal diseases (especially small intestine e.g. duodenal ulcer, liver, pancreas), e.g. gastrectomy, celiac diseases, chronic pancreatitis, cholestasis, short bowel syndrome, chronic inflammatory bowel disease (except appendicitis, gallstone surgery);
hormonal disorders, for example, Cushing's syndrome and untreated hyperthyroidism;
addiction (alcohol, drugs and/or medications);
missing consent;
refusing / reset of the consent;
simultaneous participation in another clinical trial or participation within the last 30 days;
planned surgery within the next three month
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method nausea gravidarium measured by PUQE-Score (pregnancy-unique quantification of emesis and nausea) at the beginning of the study, during the study (daily for 14 days) and at the end of the study.
- Secondary Outcome Measures
Name Time Method nausea gravidarium measured by visual analogue scale at the beginning of the study, during the study (daily for 14 days) and at the end of the study. <br><br>Vitamin B6 plasma concentration at the beginning and end of the study. <br>